U.S. insulin glargine and biosimilar market developments point to lower-cost competition

Insulin glargine and insulin biosimilars market developments in 2026 pointed to intensifying competition and lower-cost options in the United States. In January 2026, CivicaScript launched its low-cost long-acting insulin glargine-yfgn nationwide in the U.S., offering interchangeable insulin glargine pens priced at a wholesale cost of $45 for a box of five pens with a consumer price cap of $55, while California's CalRx biosimilar insulin glargine pens were set to be available to consumers beginning January 1, 2026.

Reports in January 2026 noted strong availability and distribution plans for Civica's insulin glargine across U.S. pharmacies, building on its October 2025 partnership and defining a transparent pricing model aimed at lowering long-acting insulin prices for all patients regardless of insurance status. In October 2025, Biocon Biologics and Civica expanded their strategic collaboration to include insulin glargine supply, where Biocon Biologics will manufacture and supply private-label insulin glargine to Civica for broader distribution under various branding arrangements in the U.S. market.

In the broader insulin biosimilars market, the global market reached US$ 2.5 billion in 2025 and is expected to reach US$ 6.0 billion by 2033, growing at a CAGR of 14.8% during the forecast period 2026-2033. In the United States, March 2026 developments said approval of once-weekly insulin therapies was intensifying competition, indirectly pressuring biosimilar insulin manufacturers to innovate and differentiate pricing strategies.

March 2026 reviews also emphasized ongoing uncertainty around biosimilar insulin switching, especially regarding safety, device compatibility, and therapeutic outcomes impacting broader commercialization strategies. January 2026 market analysis highlighted slow but steady adoption of insulin biosimilars, with patient and physician perception continuing to influence switching decisions and uptake in the U.S. healthcare system.

Outside the United States, in January 2026 the European Medicines Agency's CHMP recommended approval for the insulin glargine biosimilar Ondibta®, giving a positive opinion toward insulin glargine treatment for diabetes and setting the stage for future market authorization and launch in Europe. In late 2025, the CHMP decision for Ondibta was adopted, positioning this biosimilar insulin glargine for regulatory approval and eventual commercialization in EU territories as a competitive diabetes treatment option.

Additional 2026 deal activity included Amneal Pharmaceuticals' April 2026 acquisition of Kashiv BioSciences for up to $1.1 billion, a transaction described as strengthening Amneal's biosimilars pipeline, including insulin biosimilars, creating a fully integrated global biosimilars platform with development and manufacturing capabilities, and enhancing positioning in markets where insulin biologics are losing patent exclusivity.